Adults with chronic kidney disease who do not have diabetes can now benefit from finerenone, the same drug previously restricted to patients whose kidney decline was tied to type 2 diabetes. The FIND-CKD trial, a randomized study registered as NCT05047263, found that finerenone reduced kidney failure and cardiovascular-kidney composite risk in this broader population. Because non-diabetic causes of CKD account for a large share of kidney disease worldwide, the results could reshape prescribing patterns and expand access to organ-protective therapy for millions of people who had no proven pharmacologic option targeting mineralocorticoid receptor overactivation.
Why non-diabetic kidney patients stood to lose the most
Until now, the only approved use of finerenone in the United States covered adults with CKD linked to type 2 diabetes. The FDA decision to clear Kerendia focused on reducing the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attack, and heart-failure hospitalization, but only when the underlying cause was type 2 diabetes. Patients with IgA nephropathy, focal segmental glomerulosclerosis, or other non-diabetic kidney diseases were left without access to the drug, even though mineralocorticoid receptor overactivation drives fibrosis and inflammation regardless of the original cause of kidney injury.
The hypothesis that finerenone’s benefit would be strongest in patients with heavy albuminuria, specifically above 300 mg/g, rests on a reasonable biological premise: mineralocorticoid-driven fibrosis accelerates once protein leakage into the urine passes a certain threshold. The FIND-CKD trial tested finerenone across a range of non-diabetic CKD causes. Experts writing in Nature Reviews Nephrology noted that the drug’s benefits span multiple CKD etiologies, suggesting the protective mechanism is not confined to a single disease pathway. Whether the magnitude of benefit tracks with albuminuria severity in a dose-response pattern, however, will require subgroup analyses that have not yet been fully reported.
FIND-CKD and FINEARTS-HF anchor the dual-organ case
The strongest evidence for expanding finerenone’s reach comes from two large randomized trials published in the New England Journal of Medicine. The FIND-CKD report describes adults with chronic kidney disease who did not have diabetes and shows that finerenone conferred kidney protection and reduced a cardiovascular-kidney composite endpoint. The trial’s prespecified design, independently verifiable through its ClinicalTrials.gov registry record, strengthens the credibility of the findings by confirming that the endpoints were not selected after the data were collected.
Separately, the FINEARTS-HF trial tested finerenone in patients with heart failure and a left ventricular ejection fraction of 40% or higher, a population that includes many people without diabetes. That heart-failure trial showed cardiovascular benefit in the form of reduced heart-failure events. Together, the two studies build a case that finerenone protects both the kidneys and the heart across patient groups that extend well beyond the original type 2 diabetes indication.
The convergence of kidney and heart data matters because CKD and heart failure share overlapping risk pathways. Fluid retention, vascular stiffness, and chronic inflammation feed both conditions simultaneously. A single agent that lowers risk on both fronts could simplify treatment regimens and reduce the pill burden for patients already managing multiple medications. For clinicians, the practical question shifts from “does this patient have diabetes?” to “does this patient have CKD with evidence of mineralocorticoid-driven damage?”
Gaps in real-world safety, label timing, and cost data
Several questions remain open. Finerenone carries a well-documented risk of hyperkalemia, or dangerously elevated blood potassium, that requires regular monitoring. The current Kerendia label details the monitoring protocols needed for safe use. Trial settings, with their structured follow-up visits and laboratory checks, tend to catch potassium spikes early. How reliably community clinics and primary care offices will replicate that vigilance is untested. No published data yet quantify real-world adherence rates or hyperkalemia incidence outside controlled study environments.
Neither the FDA nor the drug’s manufacturer, Bayer, has publicly disclosed a timeline for seeking a formal label expansion to cover non-diabetic CKD. Without an updated indication, prescribers who want to use finerenone in non-diabetic patients would need to do so off-label, which can create insurance coverage barriers and shift liability. Cost-effectiveness analyses for the non-diabetic population have not been published, leaving unanswered whether payers will cover the drug for a much larger eligible group.
Long-term outcomes data beyond the trial follow-up window are also limited. The existing studies provide important evidence on progression to kidney failure, changes in estimated glomerular filtration rate, and major cardiovascular events, but they cannot yet show how finerenone will affect 10- or 15-year trajectories for non-diabetic CKD. Post-marketing surveillance and registry studies will be needed to track whether the benefits seen in controlled trials translate into sustained protection in routine practice, where patients are older, more heterogeneous, and often less adherent.
How clinicians might integrate finerenone now
In the near term, nephrologists and cardiologists are likely to be the first to integrate these findings into practice. For a patient with non-diabetic CKD, persistent albuminuria despite optimized renin–angiotensin system blockade, and no contraindication to mineralocorticoid receptor antagonism, the new data provide a rationale to consider finerenone, even before a label change, when insurance coverage allows. Clinicians will need to weigh the potential for kidney and heart protection against the added burden of potassium monitoring and the financial cost to the patient.
Shared decision-making will be central. Patients with slowly progressive disease and low cardiovascular risk may reasonably opt to wait for more real-world data and formal guideline endorsements. Those with rapidly declining kidney function or recurrent heart-failure admissions may be more willing to accept monitoring demands and out-of-pocket expenses in exchange for a therapy that targets a key pathway in both organs. Clear communication about benefits, risks, and uncertainties will help patients align treatment choices with their values.
Policy and research implications
For policymakers and payers, the emerging evidence raises questions about how to prioritize coverage for organ-protective drugs across disease labels. Restricting access to people with diabetes becomes harder to justify when the same mechanism of action appears to benefit patients whose kidneys failed for other reasons. Yet broad coverage without cost-effectiveness data could strain budgets, especially if finerenone is used in earlier stages of CKD where absolute event rates are lower.
Future research will need to clarify which subgroups gain the most from treatment. Detailed analyses of albuminuria strata, underlying diagnoses such as IgA nephropathy versus hypertensive nephrosclerosis, and coexisting heart failure could refine patient selection and help target therapy where it yields the greatest absolute risk reduction. Studies comparing finerenone with older steroidal mineralocorticoid receptor antagonists, as well as trials assessing combination strategies with SGLT2 inhibitors and other kidney-protective agents, will further shape the therapeutic landscape.
For now, FIND-CKD and FINEARTS-HF collectively mark a turning point: finerenone is no longer just a diabetes drug with kidney benefits, but a candidate platform therapy for cardiorenal protection across a spectrum of conditions. How quickly practice patterns, regulatory labels, and reimbursement policies adapt will determine whether that potential translates into better outcomes for the many people living with non-diabetic chronic kidney disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
